The information on this website is not intended for diagnosis or treatment. Please consult your physician for health concerns.

+90 850 321 50 00

Sotorasib and Adagrasib for KRAS G12C Mutant Non-Small Cell Lung Cancer: First Direct KRAS Inhibitors

Targeted oral therapies for previously undruggable KRAS G12C mutation in metastatic NSCLC after chemotherapy

Written by: Saygı Hospital Health Guide Editorial Board
Published:

This content is for general information; please consult your physician for diagnosis and treatment.

References (5)

This content is for informational purposes only and does not constitute medical advice. You can book an appointment at our Onkoloji department. Book Appointment →

What is Sotorasib and Adagrasib for KRAS G12C Mutant Non-Small Cell Lung Cancer: First Direct KRAS Inhibitors?

Sotorasib (AMG 510) is first FDA-approved direct KRAS G12C inhibitor with covalent binding to mutant cysteine 12 trapping inactive GDP-bound state.

Adagrasib (MRTX849) is second-in-class KRAS G12C inhibitor with similar mechanism but distinct pharmacokinetics and potential CNS activity.

KRAS G12C mutation occurs in approximately 13% of NSCLC adenocarcinoma reflecting smoking-related mutagenesis and provides actionable target.

Approval is for KRAS G12C mutant locally advanced or metastatic NSCLC after at least one prior systemic therapy.

Co-mutations including KEAP1, STK11 and TP53 affect response and prognosis with TP53 wild-type associated with better outcomes.

Symptoms

Diarrhea is common adverse effect requiring loperamide management and dose modification with severe cases.
Hepatotoxicity with transaminase elevation occurs with both agents requiring serial monitoring and dose interruption per established criteria.
Nausea, fatigue and musculoskeletal pain affect quality of life requiring supportive care and dose optimization.
QTc prolongation with adagrasib requires baseline ECG, electrolyte monitoring and concomitant medication review.
Pneumonitis and other respiratory adverse events require recognition and prompt intervention preventing progression.

Risk Factors

Smoking history correlates with KRAS G12C mutation as smoking-related transversion mutation pattern.
Co-mutations particularly STK11/KEAP1 may affect response to immunotherapy and KRAS inhibitor efficacy.
Prior chemotherapy exposure required for current approvals though first-line studies are ongoing.
Concomitant strong CYP3A4 inhibitors and inducers require dose adjustments given metabolic interactions.
Brain metastases historically poorly addressed with adagrasib showing potential CNS activity in early studies.

When to See a Doctor?

If you experience any of the following symptoms, seek medical attention promptly:

  • Newly diagnosed metastatic NSCLC adenocarcinoma should undergo molecular testing including KRAS G12C analysis directing therapy.
  • Disease progression after immunotherapy or chemotherapy in KRAS G12C mutant patients warrants targeted therapy consideration.
  • Severe diarrhea with dehydration or electrolyte abnormalities requires prompt evaluation and dose modification.
  • Significant transaminase elevation, jaundice or signs of hepatotoxicity require urgent oncology evaluation.
  • New respiratory symptoms during treatment require evaluation distinguishing pneumonitis from disease progression or infection.

Treatment Methods

01
Sotorasib 960 mg orally once daily continuous dosing represents standard regimen with food state independent absorption.
02
Adagrasib 600 mg orally twice daily continuous dosing serves as alternative agent particularly with brain metastases.
03
Diarrhea management with prophylactic and reactive loperamide, dietary modification and dose modification per established algorithms.
04
Liver function monitoring at baseline, every 2 weeks for 3 months then monthly with dose modification for transaminase elevation.
05
Resistance management with rebiopsy at progression, exploration of clinical trials with combinations and next-line systemic therapy supports comprehensive care for this evolving therapeutic area in lung cancer.

Which Department to Visit?

You can visit our Onkoloji department for these complaints. Our specialist physicians will create the most suitable treatment plan for you.

Learn About Onkoloji Department

Let us help you

You can make an appointment with our specialists or contact us for your concerns.

Book AppointmentContact Us

Related Health Topics

Other articles from the same department you may want to explore.

Anaemia

Dahiliye (İç Hastalıkları)

Anaemia is a low haemoglobin level that reduces oxygen delivery, causing fatigue, pallor, and shortness of breath. It is not a disease itself but a sign of many underlying conditions. Most cases are correctable with appropriate diagnosis and treatment.

Iron Deficiency Anaemia

Dahiliye (İç Hastalıkları)

Iron deficiency anaemia develops when dietary intake, absorption, or losses create an iron shortfall, most often affecting women and children. Identifying the underlying cause is the core of management, alongside iron replacement.

Vitamin B12 Deficiency

Dahiliye (İç Hastalıkları)

Vitamin B12 deficiency can cause megaloblastic anaemia, neurological symptoms, and cognitive impairment. Early treatment with intramuscular or oral B12 largely prevents irreversible complications.

Hypertension (High Blood Pressure) Management

Dahiliye (İç Hastalıkları)

Hypertension is often called the silent killer because it progresses symptom-free for years and can damage the heart, brain, kidneys, and eyes. Regular monitoring, lifestyle change, and evidence-based drug therapy dramatically reduce cardiovascular risk.

Chronic Kidney Disease

Dahiliye (İç Hastalıkları)

Chronic kidney disease is one of the most common complications of chronic conditions such as diabetes and hypertension, and can be silent in its early stages.

Hepatitis B (HBV)

Dahiliye (İç Hastalıkları)

Hepatitis B is a DNA virus infection causing acute and chronic hepatitis with risk of cirrhosis and hepatocellular carcinoma; diagnosis integrates HBsAg, HBeAg, anti-HBc, and HBV DNA with management based on disease phase using nucleos(t)ide analogues (entecavir, tenofovir) and universal infant vaccination.

Hepatitis C (HCV)

Dahiliye (İç Hastalıkları)

Hepatitis C is an RNA virus causing chronic hepatitis that may progress to cirrhosis and hepatocellular carcinoma; modern direct-acting antiviral (DAA) pangenotypic regimens (sofosbuvir/velpatasvir, glecaprevir/pibrentasvir) achieve sustained virologic response over 95% in 8–12 weeks with universal adult screening and cure for nearly all patients.

Fatty Liver Disease

Dahiliye (İç Hastalıkları)

Non-alcoholic fatty liver disease (NAFLD) is closely related to obesity and metabolic syndrome and is largely reversible with early treatment.

Health Disclaimer: The information on this page is prepared for general informational purposes only. It does not replace medical diagnosis and treatment. Please consult your physician for your complaints. Saygı Hospital does not accept responsibility for actions taken based on the information on this page.